Solventum Corporation (SOLV) FY2025 Earnings Quality Report

Grade: F — Major red flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Unqualified opinion (2 critical audit matters: Revenue Recognition; Divestiture of Purification and Filtration Business Gain on Sale)

One-line verdict: Solventum — the 2024 spin-off of 3M's Health Care Business — earns the worst grade in this cohort with three fails and five watch items. CFFO/NI dropped to 0.24 (C1 critical fail), cash covers only 17% of the $5.0B debt load (C4 critical fail), goodwill plus intangibles total 164% of equity (D1 fail), and the Beneish M-Score of -2.05 is in the grey zone (F1 watch). Underneath, revenue grew only 0.9% reported (3.3% organic), segment operating income was up only due to the Purification & Filtration divestiture gain, and the balance sheet carries the spin-off debt burden assumed from 3M. PwC issued two critical audit matters — revenue recognition and the P&F divestiture gain on sale.

The 3M Health Care Spin-Off

Solventum is the independent public company that emerged from 3M's 2024 separation of its Health Care Business. From the 10-K: "Unless the context otherwise requires, references to 'Solventum' and the 'Company' refer to (i) 3M's Health Care Business prior to the Spin-Off as a carve-out business of 3M and (ii) Solventum Corporation and its subsidiaries following the Spin-Off."

The company now operates in three segments: MedSurg, Dental Solutions, and Health Information Systems — plus a legacy "All Other" and a Purification and Filtration segment that was divested in September 2025.

From the MD&A: "On September 1, 2025, Solventum completed the sale of the Business to the Buyer in accordance with the terms of the Agreement. The cash consideration paid to Solventum at closing was approximately $4 billion." The buyer was Thermo Fisher Scientific.

Segment revenue breakdown from the MD&A:

Reported growth was only 0.9% because the Purification & Filtration divestiture removed ~$200M from the back half of the year.

Segment operating income from the MD&A (notable contrast):

The 110.5% jump in reported total operating income is misleading — it comes entirely from the "Corporate and Unallocated" line swinging from ($736M) in FY2024 to +$390M in FY2025. This swing reflects (a) the gain on sale of the Purification & Filtration business, and (b) the release of stranded corporate costs that existed during the transition period from 3M. The core MedSurg segment operating income actually declined 8.6% year-over-year, and Dental Solutions declined 1.1%.

The FY2025 operating cash flow drop to $369M is the most concerning number in the filing. Revenue was flat at $8.3B, so the cash flow collapse is not a revenue issue — it is a working capital or timing issue.

Cash Flow: The Collapse

Operating cash flow of $369M on net income of $1,556M — CFFO/NI ratio of 0.24. This is the C1 critical fail, and it is the most striking cash quality number across all ten reports. Free cash flow was essentially zero (negative $10M). The trend is stark: CFFO was $1,915M in FY2023 (the year before the spin-off), $1,185M in FY2024 (the spin year), and $369M in FY2025.

There are two factors. First, net income of $1,556M is inflated by the gain on sale of the Purification and Filtration business — a non-cash gain that increases reported earnings without contributing to operating cash flow. Second, the FY2025 working capital cycle was negative for several reasons that the MD&A does not cleanly break out. Even removing the estimated divestiture-gain-related net income impact, CFFO is well below normalized levels.

PwC's second critical audit matter is precisely on this divestiture gain. From the audit report: "On September 1, 2025, the sale of the Business... The cash consideration paid to Solventum at closing was approximately $4 billion." The large non-recurring gain — which inflates net income without contributing to the cash-from-operations line — is exactly why CFFO/NI dropped so sharply.

The Balance Sheet: Spin-Off Debt Overhang

Debt fell from $8.0B to $5.0B — a $3.0B reduction — after Solventum used a significant portion of the ~$4B Thermo Fisher divestiture proceeds to pay down its spin-off debt burden. Cash rose modestly from $762M to $878M. Stockholders' equity grew from $2.96B to $5.05B primarily from the divestiture gain.

Even after the paydown, cash of $878M covers only 17% of the remaining $5.0B debt — the C4 fail. Goodwill + intangibles of ~$8.3B is 164% of equity — the D1 fail. Both figures reflect Solventum's spin-off structure: the company inherited proportional goodwill and intangibles from 3M while taking on the transaction-related debt.

The 18-Point Screening

Revenue Quality

Revenue quality is clean at the basic check level. DSO is tight at 45 days — one of the lowest in our medical supplies coverage. AR actually declined 1% while revenue grew 0.9%. The MD&A does not suggest channel stuffing. A3 passes technically because revenue grew less than 10% (the engine's rule for A3 requires both revenue growth > 10% and CFFO < 30% of that to fail).

However, the 68.9% CFFO decline is a standout red flag at the narrative level and is captured by the C1 fail below.

Expense Quality

B4: Gross margin declined 220bp from 55.6% to 53.5%. Over the three-year trend (57.7% → 53.5%), the decline is 420bp — meaningful compression that reflects the transition from being part of 3M's manufacturing base to running as an independent operation.

B1: Inventory grew 10.5% — more than 2x the COGS growth — but still within the pass rule. Worth monitoring in future periods.

Cash Flow Quality

C1 (critical fail): CFFO/NI of 0.24 means only 24% of reported profit was backed by operating cash. The mathematical driver is the gain on the Purification & Filtration divestiture — a ~$1.0B+ non-cash gain that inflates net income. Adjust for that, and the ratio is still below 1.0, but not catastrophically so. The headline ratio is the one that matters for the mechanical grade.

C2 (watch): Free cash flow was negative $10M for FY2025. The MD&A confirms CapEx of $379M was held steady; operating cash flow could not fund it.

C3 (watch): Accruals ratio of 8.3% is elevated. This is the positive-signed variant — meaning accrual earnings exceeded cash earnings — which is a moderate signal that current-period profits will be harder to collect. Combined with the C1 fail, this reinforces the picture that reported net income is not currently supported by cash generation.

C4 (critical fail): Cash of $878M covers 17% of debt of $5,035M. Even after the $3B debt paydown from divestiture proceeds, the coverage is inadequate.

Balance Sheet

D1 (fail): Goodwill + intangibles of ~$8.3B exceed stockholders' equity of $5.05B. The 164% ratio is the highest in this cohort. This is the direct structural result of the 3M carve-out — Solventum inherited all the brand value and acquired intangibles of the legacy 3M Health Care Business without having the organic equity base to cushion it.

D2 (watch): Interest coverage of 1.8x is below the 2.0x watch threshold. With $5.0B of debt and elevated interest rates, interest expense consumes a material portion of operating income.

D3 (watch): Other assets grew 22.4% against revenue of 0.9%. This likely reflects divestiture-related receivables, deferred tax assets from the gain, or escrow balances tied to the Thermo Fisher transaction.

M&A Risk

Goodwill + intangibles declined 7% YoY primarily from the Purification & Filtration divestiture removing allocated goodwill. Solventum acquired Acera in December 2025 but it was a small bolt-on.

Beneish M-Score

F1 (watch): M-Score of -2.05 is in the grey zone — above the -2.22 clean threshold but below the -1.78 manipulation zone. The DSRI is clean (DSO actually improved), but the TATA component (total accruals to total assets) is contributing negative signal from the accruals pattern above.

Critical Audit Matters: Two of Them

PwC identified two critical audit matters — unusual for a straightforward manufacturing business and a signal that this is a particularly complex audit.

CAM #1: Revenue Recognition

From the audit report: "The Company's net sales of product and net sales of software and rentals were $6,349 million and $1,976 million, respectively, for the year ended December 31, 2025. The principal consideration for our determination that performing procedures relating to revenue recognition is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company's revenue recognition."

Solventum has a mix of point-in-time product revenue, subscription-style software revenue, and equipment rental revenue for the Health Information Systems business. PwC's procedures included "confirming a sample of outstanding customer invoice balances as of December 31, 2025 for product, software, and rental revenue transactions." Revenue testing is extensive.

CAM #2: Divestiture of Purification and Filtration Business Gain on Sale

From the audit report: "on February 25, 2025, the Company entered into a Transaction Agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc... On September 1, 2025, the sale of the Business [was completed]."

The gain-on-sale calculation involves determining the carve-out basis of the divested business, allocating goodwill, and recognizing the difference against $4B of cash consideration. The complexity of allocating goodwill from a segment that was itself a carve-out from 3M's Health Care Business (which was itself a carve-out from 3M) makes this an especially challenging audit area. The P&L impact shows up as the ~$1.1B Corporate and Unallocated swing noted above.

PwC has served as Solventum's auditor since the spin-off, and before that audited 3M Health Care as part of the 3M consolidated group (PwC has been 3M's auditor for decades).

Key Risks from Item 1A

1. Spin-off debt burden. From Item 1A: "the debt obligations incurred by Solventum in connection with the separation will adversely affect its profitability and could affect its ability to use its cash flow for investing in the business, strategic transactions, including mergers and acquisitions, and returning capital."

2. Loss of 3M brand and operational leverage. From Item 1A: "Solventum benefited from 3M's long operating history, reputation and well-known brand. Following the separation, Solventum is operating under its own brand, and accordingly may be negatively impacted due to the loss of benefits conferred by 3M's brand recognition and reputation."

3. Medical device regulatory complexity. Item 1A spends extensive text on FDA, EU MDR, NMPA (China), HIPAA, CCPA, GDPR, and PIPL compliance requirements. The Advanced Wound Care and Infection Prevention product lines carry significant regulatory surface area.

4. Separation costs and stranded overhead. The FY2024 Corporate and Unallocated loss of ($736M) and the FY2025 swing to +$390M reflect the stranded-cost normalization. Future period costs are expected to reflect the standalone structure more fully.

5. Carve-out financial statement limitations. From the MD&A: "Solventum utilized allocations and carve-out methodologies through the date of the Spin-Off to prepare combined financial statements. The consolidated financial statements herein for periods prior to the Spin-Off may not be indicative of the Company's future performance, do not necessarily include the actual expenses that would have been incurred."

6. Ongoing restructuring. Corporate is in the process of exiting Transition Services Agreements with 3M; costs may rise as standalone structure replaces shared services.

Altman Z-Score and F-Score

Z-Score of 2.28 is the only Z-Score in this ten-ticker cohort in the grey zone — all other companies are safely above 2.99. The main contributors are high debt relative to total market value and the low working-capital-to-total-assets ratio. The F-Score of 0.56 is low, consistent with the M-Score grey zone reading (these two models weight different factors and the F-Score is less sensitive to the gain-on-sale effect that pushed the M-Score up).

Summary

Grade: F. Three fails, two of them critical (C1 and C4).

Solventum earns the weakest grade in this cohort. Three fails (C1, C4, D1), five watches (C2, C3, D2, D3, F1), a Z-Score in the grey zone, and two PwC critical audit matters. The underlying cause is twofold: (a) the company inherited a heavy debt load from the 3M spin-off that the current cash generation cannot service comfortably, and (b) the FY2025 net income was inflated by a ~$1B+ non-cash gain on the Purification & Filtration divestiture that did not translate into operating cash flow.

What this does NOT mean: Solventum is not manipulating earnings. The divestiture gain is legitimate and fully disclosed. PwC's two critical audit matters are complex-transaction issues, not fraud risk indicators. The M-Score grey zone reflects the unusual accruals pattern around the divestiture rather than hidden aggressive accounting.

What this DOES mean: the FY2025 headline net income number is not a sustainable run rate, the CFFO collapse is real, and the balance sheet is still in transition to its post-spin-off normalized state. FY2026 will be the first full year without the Purification & Filtration business and without legacy 3M cost allocations — the run-rate economics should become clearer. Until that happens, the business is carrying three structural red flags that keep the screening grade at F.

**Disclaimer**: This report is based on Solventum's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 2 critical audit matters: Revenue Recognition; Divestiture of Purification and Filtration Business Gain on Sale)